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Abstract
OBJECTIVE: We compared bone mineral density (BMD) changes and their correlates, between 
men and women participating in two randomized trials of initial (ART) regimens, with or without 
tenofovir disoproxil fumarate (TDF).
METHODS: Covariates in linear regression models of 48-week hip and spine %BMD changes, by 
dual energy X-ray absorptiometry, included baseline and 48-week changes in plasma viral load 
(pVL), CD4 cells, plasma C-terminal telopeptide, procollagen 1 N–terminal propeptide and 
glomerular filtration rates; and the 48-week area under the curve of fractional excretion of 
phosphate (FEP-AUC).
RESULTS: Despite overall hip and spine BMD declines of 2.8% and 2.9%, respectively, pVL 
suppression to <50 vs. ≥50 copies/mL was associated 1.0% (P=0.02) and 0.8% (P=0.01) less BMD 
decline. Women had lower baseline spine (P=0.04; n=59 women, 418 men) and hip BMD 
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(P=0.01) in adjusted models, with 1.7% more hip decline on ART than men (P=0.001). Serum 
phosphate was positively associated with baseline spine BMD in women (P=0.03) but not men, 
and FEP-AUC was negatively associated with spine BMD changes, particularly in women 
randomized to TDF-regimens (P=0.03 & 0.054 for interactions by sex, and randomization to TDF 
vs. non TDF-regimens, respectively; n= 44 women, 326 men). Women also had 0.6% (P=0.004) 
more hip BMD decline than men associated with each 100 CD4 cell/μL increase on ART (P=0.02; 
n=49 women, 379 men).
CONCLUSIONS: Women randomized to TDF-containing ART had accentuated spine loss 
associated with phosphaturia, and accentuated hip loss associated with CD4 restoration, regardless 
of TDF-exposure. Viral load suppression reduced bone loss.
INTRODUCTION
Persons living with HIV (PLWH) on antiretroviral therapy (ART) have a higher prevalence 
of osteoporosis and an increased fracture risk compared to the general population (1–4). 
Average bone mineral density (BMD) declines of 2 to 6% develop predominately during the 
first year of ART, and the largest of these are associated with regimens that include tenofovir 
disoproxil fumarate (TDF) or protease inhibitors (5–8). In a large sample of PLWH in the 
US, the incidence of fracture increased from 1.78 per 100 person-years (py) in those with 
normal BMD, to 2.10 and 7.62 per 100 py, in those with osteopenia and osteoporosis, 
respectively (9). Among U.S. Veterans with HIV, increasing cumulative exposure to TDF or 
protease inhibitors was associated with higher incidence of fracture (10). PLWH also have 
an over-representation of traditional risk factors for bone loss, which combined with the 
detrimental effects on bone by ART and other HIV-specific factors, also contribute to lower 
BMD and increased fracture risk (10–13).
Among PLWH, women have faster rates of bone loss, maintain lower BMD and have higher 
rates of fracture than men (3, 14, 15). It is not known whether, or to what extent the 
detrimental effects of ART on bone, or other HIV-specific correlates of bone loss, differ 
between men and women. To examine this question, we compared hip and spine BMD 
changes, and their correlates, between men and women during the first 48 weeks of initial 
ART in participants of two multicenter AIDS Clinical Trials Group randomized trials 
(ACTG studies A5224s and A5303).
METHODS
Study Design and Treatment Regimen
A5224s is a metabolic substudy of a larger trial that compared TDF–emtricitabine vs. 
abacavir–lamivudine, combined with either efavirenz or atazanavir plus ritonavir as initial 
ART (5, 16). A5303 compared initial ART with TDF vs. maraviroc, each combined with 
emtricitabine and darunavir plus ritonavir (17). ART-naïve participants with plasma VL 
>1,000 copies/mL, who were ≥16 years for A5224s, or ≥18 years for A5303, were eligible 
to participate. Eligibility for A5224s was additionally restricted to participants who did not 
use medications for osteoporosis, and eligibility for A5303 was restricted to participants 
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with R5 tropism. Additional information can be found about these studies at 
ClinicalTrials.gov: NCT 00118898 and 01400412.
The Institutional Review Board of each study site approved the protocol. All participants 
provided written informed consent.
Measurements of BMD, Phosphaturia and Bone Turnover
Dual energy X-ray absorptiometry (DXA) scans of the left hip and lumbar spine (L1-L4) 
were performed within 4 weeks prior to randomization, using either a Lunar [GE Healthcare, 
Fairfield, Connecticut] or Hologic [Hologic Incorporated, New Bedford, Massachusetts] 
DXA scanner. A second scan was performed at week-48 (±4 weeks) using the same 
scanning system. All DXA scans were read centrally at the Body Composition Analysis 
Center at Tufts University. The European Spine Phantom was used for cross-calibration of 
DXA machines and quality assurance at each study site.
Phosphaturia was measured as the week 0 to 48 area under the curve of the fractional 
excretion of phosphate (FEP-AUC) from urine and serum specimens collected at weeks 0 
and 48, calculated using the trapezoidal rule (18, 19).
Bone turnover was measured in A5303 participants only, at weeks 0, 24 and 48 in plasma as 
C-terminal telopeptides of type I collagen (CTx), and procollagen 1 intact N–terminal 
propeptide (P1NP). CTx was measured by ELISA (Immunodiagnostic Systems, Scottsdale, 
Arizona) with inter- and intra-assay variabilities of 9.7% and 1.7%, respectively (normal 
range: 0.142–1.351 pg/mL for postmenopausal women). P1NP was measured by 
radioimmunoassay (Immunodiagnostic Systems, Scottsdale, Arizona) with inter- and intra-
assay variabilities of 8.3 and 6.5%, respectively (normal range 16–96 pg/mL for 
postmenopausal women).
Statistical Analysis
Baseline, and 48-week changes from baseline, in time-varying covariates were compared by 
sex, and by randomization to TDF vs. non TDF-containing regimens, using the Wilcoxon 
rank-sum test for continuous, and the Pearson chi-square test for categorical variables. 
Baseline for all covariates except BMD was defined as the randomization date (designated 
as week 0); baseline for BMD measurements were defined as up to 4 weeks before 
randomization. The exploratory covariates included baseline serum phosphate and 48-week 
FEP-AUC, as well as baseline and 48-week changes from baseline in: CD4 cell counts, 
glomerular filtration rates (using the CKD-EPI equation), CTx and P1NP.
Separate multivariable linear regression models tested the independent contributions to 
baseline hip and spine BMD, and to the 48-week changes from baseline of BMD by each 
exploratory variable. Adjusting variables that were retained in the models regardless of 
significance included age, sex, race (as black, not Hispanic vs. white, Hispanic regardless of 
race, and other races/ethinicities), baseline hip or spine BMD, randomization status to TDF 
vs. non TDF-containing regimens, baseline plasma viral load (pVL), and pVL at week-48 
(as <50 vs. ≥50 copies HIV-RNA/mL). Models of hip BMD were additionally adjusted for 
baseline body mass index (BMI).
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These models were extended to test interactions by sex and randomization status, where 
significance was defined by P<0.10. Stratified, unadjusted models by sex and randomization 
status explored any significant interactions that were detected. All analyses used SAS 
version 9.4 [SAS Institute, Cary, North Carolina].
RESULTS
Included in this analysis were 499 participants, 433 of whom had baseline and week-48 hip 
or spine BMD measurements [Table 1]. Complete CD4 cell and phosphaturia data was 
available in 429 and 374 of these 433 participants, respectively. Turnover markers were 
measured only in A5303 participants (n=220). Data from participants who represented 
extreme outliers in the distributions of hip BMD changes (n=3), or of the 48-week area 
under the curve of FEP-AUC (n=4) was excluded for the linear regression models.
Participants randomized to TDF vs. non TDF-containing regimens had significantly more 
hip (3.6 % vs. 2.4%, P<.0001; Table 2) and spine BMD decline (3.6 % vs. 1.9%, P<.0001). 
They also had significantly larger increases in bone turnover markers (P<.0001, for CTx and 
P1NP), greater 48-week FEP-AUC (P=0.01) and more GFR decline (4.33 vs. 0.54 ml/min/
1.73m2, P=0.004).
Sixty-one (12%) participants were women, who were significantly older (40 vs. 37 years, 
P=0.02) and more likely to be black than the men (28% vs. 48%, P<.0001). They also had 
significantly higher baseline BMI (P=0.03) and serum phosphate concentrations (P=0.001), 
significantly lower FEP-AUC (P=0.03), and a trend towards larger increases in the bone 
formation marker P1NP (P=0.07).
Correlates of Baseline Spine BMD
Women had a 0.39 g/cm2 (P=0.04) lower average baseline spine BMD than men in adjusted 
models. Baseline BMI (P<.0001) and serum phosphate concentrations were positively 
associated with baseline spine BMD, but the latter association depended on sex (P=0.04 for 
the interaction by sex; n=49 women, 427 men; Figure 1A & Supplementary Table). In 
stratified analyses, serum phosphate was positively associated with BMD in women 
(P=0.03) but not men (P=0.97).
Baseline & Time-varying Correlates of 48-Week Spine BMD Changes
Participants randomized to TDF vs. non TDF-containing regimens had a 1.8% larger average 
spine BMD decline (P<0.0001) in adjusted models [Supplementary Table]. BMD change 
was positively associated with baseline spine BMD (P=0.0002), negatively associated with 
baseline pVL (1.3% greater decline per every 1 log10 greater HIV RNA copies/mL; P<.
0001) and positively associated with viral suppression at week-48 (1.0% less BMD decline 
with suppression to <50 vs. ≥50 copies/mL; P=0.02). Women had a 0.6% larger average 
BMD decline than men, but this difference was not significant (P=0.35).
Phosphaturia, baseline and ΔCD4 cells, ΔGFR and bone turnover markers were significantly 
associated with 48-week spine BMD changes in separate, adjusted models [Supplementary 
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Table]. Sex modified associations with phosphaturia; and randomization status modified 
associations with phosphaturia and ΔGFR.
Each 2% increased FEP-AUC was associated with a 0.8% (P=0.03) larger average spine 
BMD decline in women vs. men, and with a 0.4% (P=0.054) larger average decline in 
participants randomized to TDF vs. non TDF-containing regimens [Supplementary Table]. 
In analyses stratified by sex among participants randomized to TDF-regimens, this 
magnitude of phosphaturia was associated with a 1.4% average decline in women (P=0.03, 
Figure 1B), but was not significantly associated with BMD changes in men (P=0.17). 
Phosphaturia was not associated with BMD spine changes in participants randomized to non 
TDF-containing regimens, regardless of sex.
Associations between ΔGFR and spine BMD decline also depended on randomization 
status. A 5 ml/min*1.73 m2 GFR decline over 48 weeks was associated with a 0.4% larger 
average BMD decline in participants randomized to TDF vs. non TDF-regimens (P=0.01 for 
the interaction by randomization status; Figure 1C & Supplementary Table). In stratified 
analyses, this association was also only significant among participants randomized to TDF-
regimens (P=0.01).
Changes in spine BMD on ART was negatively associated with ΔCD4, with an average 
BMD decline of 0.3% for every 100 CD4 cells/μL increase (P=0.02). Although the effect 
size associated with this CD4 cell increase was larger in women (0.8%, P=0.01) than men 
(0.3%, P=0.04), these differences were not significant (P=0.38 for the interaction by sex; 
n=49 women and 379 men; Figure 2A & Supplementary Table).
Each 1 S.D. increased CTx over 24 weeks, or increased P1NP over 48 weeks, was associated 
with average spine BMD declines of 0.7% (P=0.02) and 1.1% (P<.0001; Supplementary 
Table), respectively. The small number of women with turnover markers (n=19) precluded 
reliable comparisons by sex. If bone resorption was instead estimated by 48-week changes 
from baseline in CTx, the strength of association fell to a 0.5% average BMD decline 
(P=0.08). Plasma CTx and absolute CD4 cell counts were weakly correlated (r=0.16, 
P=0.01; r=0.12, P=0.06; and r=0.11, P=0.09 at weeks 0, 24 and 48, respectively).
Correlates of Baseline Hip BMD
Women had a 0.05 g/cm2 (P=0.01) lower average baseline hip BMD than men in adjusted 
models. Baseline hip BMD was negatively associated with age (P<.0001), positively 
associated with baseline BMI (P<.0001), and black participants had larger baseline hip 
BMD than non-blacks (P=0.01). In contrast to the spine, serum phosphate was not 
associated with baseline hip BMD.
Baseline & Time-Varying Correlates of 48-Week Hip BMD Change
Participants randomized to TDF vs. non TDF-containing regimens had a 1.5% (P<.0001) 
larger average hip BMD decline in adjusted models, and women had a 1.7% (P=0.001) 
larger decline than men. Hip BMD changes were positively associated with baseline hip 
BMD (P=0.001), negatively associated with baseline pVL (0.6% per each 1 log10 greater 
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HIV-RNA copies/mL; P=0.003), and positively associated with pVL suppression to < 50 vs. 
≥ 50 copies/mL at week-48 (0.8% less BMD decline, P=0.01; Supplementary Table).
Changes in hip BMD were associated with baseline and ΔCD4 cells and turnover markers 
[Supplementary Table], but neither phosphaturia nor ΔGFR were associated with hip BMD 
changes. Each 100 fewer baseline CD4 cells/μL was associated with a 0.1% larger average 
BMD decline (P=0.02), while sex modified associations with ΔCD4 so that women had an 
average 0.6% more BMD decline than men for every 100 CD4 cell/μL increase (P=0.02 for 
the interaction by sex; n=48 women, 376 men; Figure 2B). In stratified analyses, this 
magnitude of CD4 increase was associated with an average BMD decline of 0.9% (P=0.003) 
in women, but ΔCD4 was not associated with BMD changes in men (P=0.59).
Each 1 S.D. increased CTx and P1NP over 48 weeks was associated with a 0.5% (P=0.02), 
and 0.7% (P=0.001) average hip BMD decline, respectively. In contrast to the spine, the 
strength of association between CTx fell to 0.3% (P=0.14) if bone resorption was instead 
estimated by 24-week changes from baseline in this marker.
DISCUSSION
In this pooled analysis of 2 randomized trials comparing 48-week BMD changes with the 
initiation of TDF vs. non-TDF regimens in HIV-infected ART naïve persons, we observed 
significant differences in the correlates of bone loss that depended on bone site (spine vs. 
hip), sex and TDF-exposure. Participants randomized to TDF-containing regimens had 
accentuated spine BMD loss associated with phosphaturia, particularly among women. 
Women also had significantly more hip loss than men associated with CD4 restoration, 
regardless of TDF-exposure. Despite overall spine and hip BMD declines of 2.8% and 2.9%, 
respectively, with initial ART, pVL suppression to < 50 vs. ≥ 50 copies/mL was associated 
with 1.0% and 0.8% less BMD loss.
Bone turnover is a synchronized process of osteoclast-derived resorption, osteoblast-derived 
collagen matrix deposition and mineralization. Plasma CTx, a marker of bone resorption, 
increases within 2 weeks after initiating ART, reaching peak levels by 24 weeks (20). 
Plasma P1NP, a marker of new bone formation involving type I collagen matrix deposition, 
reaches peak levels approximately one year after ART initiation (21). In the present study, 
the differential associations of spine vs. hip ΔBMD with ΔCTx when comparing 24- and 48-
week changes from baseline, suggests earlier resorption of spine (predominately composed 
of trabecular bone) than hip (predominately cortical bone), a dynamic that is also evident 
with perimenopausal bone loss (22).
The mineralization of collagen fibrils by osteoblasts incorporates carbonated hydroxyapatite, 
whose source of calcium and phosphate is derived from serum (23). Serum phosphate is 
tightly regulated by parathyroid hormone and fibroblast growth factor-23 via intestinal 
phosphate absorption, and by phosphate reabsorption in the proximal renal tubules (24). As 
in the present study, menopausal women retain phosphate, maintaining higher serum 
concentrations with lower urinary phosphate excretion than men or pre-menopausal women 
(25). The positive association between serum phosphate and baseline spine BMD among 
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women in the present study also is consistent with a similar previous association in 
postmenopausal women (26). These observations implicate contributions by menopausal 
bone loss to the differential associations by sex, between markers of phosphate homeostasis 
and changes in spine BMD. Because bone mineralization is a late step in remodeling, the 
differential associations with phosphaturia between spine and hip similarly implies earlier 
remodeling of the spine.
Consistent with previous studies, participants randomized to TDF-containing regimens had 
significantly larger increases in bone turnover markers, which were associated with BMD 
declines (6, 13, 20, 27, 28). TDF also may induce a proximal renal tubulopathy leading to 
urinary phosphate wasting, with or without GFR reductions, by engaging drug transporters 
in the renal tubular membrane (29–31). The risk for tubulopathy may be accentuated by 
concomitant protease inhibitor-use, including ritonavir, which also may directly engage 
these renal drug transporters, or enhance TDF exposure via drug-drug interactions (32, 33). 
This tubulopathy has been postulated as a mechanism of BMD decline with TDF (27, 34), 
but evidence for this effect is conflicting.
A previous analysis of A5224s participants did not detect an association between 
phosphaturia (as FEP) and hip or spine BMD changes (35). In this subset, the association 
between FEP-AUC and spine BMD decline was not significant among women (r=0.13, 
P=0.52, n=27), or in those randomized to TDF-containing regimens (r=0.14, P=0.18, n=90) 
probably because of the smaller sample size. In a second study of men with HIV receiving 
TDF, the urinary retinol-binding protein to creatinine ratio (a marker of renal tubule 
dysfunction), but not FEP, was negatively associated with spine BMD (36). In a third 
longitudinal study of mostly men with HIV who received TDF, phosphaturia (as FEP) was 
negatively associated with femoral neck BMD decline, a site with approximately equal 
proportions of trabecular and cortical bone (37). Tenofovir alafenamide (TAF) achieves 
higher intracellular accumulation, with lower plasma concentrations, and is associated with 
significantly less tubulopathy and BMD decline than TDF (38). In adults with low BMD, 
switching from TDF to TAF was associated with increased hip BMD, which was predicted 
by higher FEP (39). Although it is difficult to reconcile these disparate observations, the 
significant associations between phosphaturia as well as GFR changes, with early spine 
BMD loss in the present study supports an interpretation of TDF-mediated renal tubulopathy 
leading to impaired trabecular bone mineralization, particularly affecting women.
Among HIV specific factors, CD4 cell increases, nadir CD4 cell counts, and pre-ART pVL 
were previously associated with BMD loss after ART-initiation (11, 20). The importance of 
T-cell restoration in ART-associated bone loss is supported by an animal model simulating 
ART-associated immune restoration that adoptively transferred T-cells from healthy mice 
into T-cell receptor knockout mice (40). Consistent with the present study, CTx levels were 
previously correlated with CD4 cell counts in HIV patients who initiated ART (20). We 
extend this observation by demonstrating more hip loss, for the same magnitude of CD4 
restoration in women than men. Previous studies have demonstrated negative associations 
between BMD and pVL suppression on ART (41). Although we also observed net 
detrimental effects by initial ART on BMD, we detected salutary effects by pVL 
suppression.
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This study is limited by a relatively small number of women. Menstrual history and 
biological markers of menopause also were not captured in women, nor was the history of 
current or past tobacco or alcohol use among all participants. Bone turnover markers were 
measured in A5303 participants only, precluding reliable comparisons by sex with these 
markers. Nevertheless, the prospective study design with uniform measurements of BMD 
and other exploratory variables, in the context of randomized, initial ART regimens are 
major strengths of this study.
Upon ART-initiation, women who received TDF had enhanced spine BMD loss compared to 
men in association with phosphaturia. Women also had larger hip and spine BMD declines 
for the same magnitude of CD4 cell restoration as men, regardless of TDF exposure. Despite 
overall BMD declines with initial ART, viral suppression mitigated bone loss. The complex 
interactions that we observed involving bone site, sex and TDF-exposure may be explained 
by simultaneous and overlapping effects of perimenopausal bone loss, TDF-associated bone 
toxicity, adverse bone effects by immune restoration and beneficial effects of viral 
suppression. Because of the importance of bone health among PLWH, a better understanding 
of these sex differences in ART-associated BMD loss is warranted.
Interventions that have been shown to reduce early bone loss at the time of ART initiation 
include high dose vitamin D and calcium supplementation and single dose zoledronic acid 
(42, 43). BMD also improves when switching from TDF to TAF (38), or to other non-TDF 
containing regimens, but TDF remains a critical component of ART particularly in low-
income countries where the majority of PLWH are women.
Clinicians are encouraged to screen for bone disease, avoid TDF and ritonavir-boosted 
protease inhibitors in patients at risk for fragility fractures, and to advise patients about 
preventative measures including lifestyle assessments, and considerations for vitamin D and 
calcium supplementation (44).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We are grateful to the participants of this study.
Funding
The project described was supported by Award Number U01AI068636 from the National Institute of Allergy and 
Infectious Diseases and supported by National Institute of Mental Health (NIMH), National Institute of Dental and 
Craniofacial Research (NIDC ), the Veterans Administration: VISN10 Geriatric Research Education and Clinical 
Centers, Louis Stokes Cleveland Veterans Administration Medical Center, and the research sites that participated: 
[grant numbers UMAI069494, UMAI069432, UM1AI 069471, UM1AI069452, UM1 AI069501, 2UM1AI069432, 
UL1 TR001082, 1U01AI069477-01, P30AI073961, 5UM1 AI068636, 2UM1AI069503, UM1 AI069471, 
2UM1AI069439-08, and UL1 TR000445 from the National Center for Advancing Translational Sciences/NIH 
AI69439, UM1 AI069496, 5UM1AI069412, UM1 AI069423, 1UL1TR001111, P30 AI50410, 2UMIA1069423-08, 
2UM1AI069418-08, 2P30 AI 50409-10, UL1TR000454, AI069501, 5UM1AI069415-10, 2UM1AI069412-08, 
AI069424, UL1 RR025780, 2UM1 AI069470-08, UM1AI069472, 2UMAI069432, AI 69501, UM1AI069471, 
UM1A 068636-09, 5 P30 AI- 045008-15, U01AI069447, NO1-HD-3-3345, UMI AI069511, UM1 AI069465, 
UL1TR001079, UL1 RR024160, UL1 TR000042, and from the Center for AIDS Research AI 036219]. ViiV, 
Gilead, and AbbVie provided study drugs. ViiV provided funding for DXA scanning. The content is solely the 
Kalayjian et al. Page 8
AIDS. Author manuscript; available in PMC 2019 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy 
and Infectious Diseases or the National Institutes of Health
REFERENCES
1. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral 
density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 
2007;21(5):617–23. [PubMed: 17314524] 
2. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and 
high-energy fractures in persons with and without HIV infection: a Danish population-based cohort 
study. AIDS. 2012;26(3):285–93. [PubMed: 22095195] 
3. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency 
virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin 
Endocrinol Metab. 2008;93(9):3499–504. [PubMed: 18593764] 
4. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, Investigators HIVOS. Increased rates of bone 
fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US 
general population, 2000–2006. Clin Infect Dis. 2011;52(8):1061–8. [PubMed: 21398272] 
5. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and 
fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir 
disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials 
Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–801. [PubMed: 
21606537] 
6. Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, et al. Bone mineral density 
and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or 
tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/
ANRS143 randomised trial. Lancet HIV. 2015;2(11):e464–73. [PubMed: 26520926] 
7. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in 
bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse 
transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23(7):817–24. 
[PubMed: 19363330] 
8. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison 
of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in 
HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–72. 
[PubMed: 20828304] 
9. Battalora L, Buchacz K, Armon C, Overton ET, Hammer J, Patel P, et al. Low bone mineral density 
and risk of incident fracture in HIV-infected adults. Antivir Ther. 2016;21(1):45–54. [PubMed: 
26194468] 
10. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with 
cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31. 
[PubMed: 22301411] 
11. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ 
count is associated with greater bone mineral density loss after antiretroviral therapy initiation. 
Clin Infect Dis. 2013;57(10):1483–8. [PubMed: 23943825] 
12. Kooij KW, Wit FW, Bisschop PH, Schouten J, Stolte IG, Prins M, et al. Low bone mineral density 
in patients with well-suppressed HIV infection: association with body weight, smoking, and prior 
advanced HIV disease. J Infect Dis. 2015;211(4):539–48. [PubMed: 25180239] 
13. Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, et al. Comparison of 
bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a 
randomized trial. PLoS One. 2012;7(3):e32445. [PubMed: 22479327] 
14. Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, Brady JJ, et al. Relative contribution of 
HIV infection, demographics and body mass index to bone mineral density. AIDS. 2014;28(14):
2051–60. [PubMed: 25265073] 
15. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total 
bone mineral density over time in HIV-infected men and women in the nutrition for healthy living 
study. J Acquir Immune Defic Syndr. 2008;49(3):298–308. [PubMed: 18845956] 
Kalayjian et al. Page 9
AIDS. Author manuscript; available in PMC 2019 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine 
versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: 
final results. J Infect Dis. 2011;204(8):1191–201. [PubMed: 21917892] 
17. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, et al. Less Bone Loss 
With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials 
Group A5303 Study. Clin Infect Dis. 2015;61(7):1179–88. [PubMed: 26060295] 
18. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice 
guideline for the management of chronic kidney disease in patients infected with HIV: 2014 
update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin 
Infect Dis. 2014;59(9):e96–138. [PubMed: 25234519] 
19. Psyrogiannis A, Kyriazopoulou V, Symeonidis A, Leotsinidis M, Vagenakis AG. Relative iron 
“overload” in offspring of patients with type 2 diabetes mellitus: a new component in the 
conundrum of insulin resistance syndrome? Hormones (Athens). 2003;2(3):161–8. [PubMed: 
17003017] 
20. Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, et al. Antiretroviral 
therapy induces a rapid increase in bone resorption that is positively associated with the magnitude 
of immune reconstitution in HIV infection. AIDS. 2016;30(3):405–14. [PubMed: 26760232] 
21. Murray BF, van Vonderen MG, Mallon PW, Doran P, van Agtmael MA, Danner SA, et al. Changes 
in bone biomarkers in antiretroviral naive HIV-infected men randomised to nevirapine/lopinavir/
ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help 
explain limited loss of bone mineral density over first 12 months. Bone. 2012;50:S167–S.
22. Seeman E Age- and menopause-related bone loss compromise cortical and trabecular 
microstructure. J Gerontol A Biol Sci Med Sci. 2013;68(10):1218–25. [PubMed: 23833200] 
23. Clarke B Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3:S131–9. 
[PubMed: 18988698] 
24. Lederer E Regulation of serum phosphate. J Physiol. 2014;592(18):3985–95. [PubMed: 24973411] 
25. Bansal N, Katz R, de Boer IH, Kestenbaum B, Siscovick DS, Hoofnagle AN, et al. Influence of 
estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal 
women: the MESA study. J Clin Endocrinol Metab. 2013;98(12):4890–8. [PubMed: 24092825] 
26. Collins D, Jasani C, Fogelman I, Swaminathan R. Vitamin D and bone mineral density. Osteoporos 
Int. 1998;8(2):110–4. [PubMed: 9666932] 
27. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, et al. Low bone mineral density, 
renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 
2009;200(11):1746–54. [PubMed: 19874178] 
28. Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A, et al. Changes in bone turnover and 
bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-
lamivudine. PLoS One. 2012;7(6):e38377. [PubMed: 22719882] 
29. Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of 
HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199–212. [PubMed: 
25350530] 
30. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir 
nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial 
abnormalities. Kidney Int. 2010;78(11):1171–7. [PubMed: 20811330] 
31. Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, et al. Fanconi 
syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a 
prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 
2014;9(3):e92717. [PubMed: 24651857] 
32. Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, et al. Risk of Chronic 
Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing 
Antiretroviral Treatment. PLoS One. 2016;11(9):e0162320. [PubMed: 27632369] 
33. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety 
of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune 
Defic Syndr. 2006;43(3):278–83. [PubMed: 17079992] 
Kalayjian et al. Page 10
AIDS. Author manuscript; available in PMC 2019 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
34. Borderi M, Gibellini D, Vescini F, De Crignis E, Cimatti L, Biagetti C, et al. Metabolic bone 
disease in HIV infection. AIDS. 2009;23(11):1297–310. [PubMed: 19550284] 
35. Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, et al. Bone mineral density 
reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary 
analysis of ACTG A5224s. J Antimicrob Chemother. 2017;72(7):2042–8. [PubMed: 28369419] 
36. Hamzah L, Samarawickrama A, Campbell L, Pope M, Burling K, Fisher M, et al. Effects of renal 
tubular dysfunction on bone in tenofovir-exposed HIV-positive patients. AIDS. 2015;29(14):1785–
92. [PubMed: 26372384] 
37. Casado JL, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A, et al. Bone mineral density 
decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected 
patients. AIDS. 2016;30(9):1423–31. [PubMed: 26919733] 
38. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir 
disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial 
treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 
2015;385(9987):2606–15. [PubMed: 25890673] 
39. Brown T, Yin MT, Gupta S, Katalama C, Lazzarin A, Melborne K, et al. Switching from TDF to 
TAF in HIV-infected adults with low BMD: A pooled analysis. Conference on Retroviruses and 
Opportunistic Infections, Seattle WA Feb 13–16, 2017:Abstract #683.
40. Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, et al. Role of T-cell 
reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun. 2015;6:8282. 
[PubMed: 26392000] 
41. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. 
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 
2008;22(3):395–402. [PubMed: 18195566] 
42. Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, et al. A Single-dose 
Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive 
HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis. 2016;63(5):663–71. [PubMed: 
27193748] 
43. Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, et al. Vitamin D and 
Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann 
Intern Med. 2015;162(12):815–24. [PubMed: 26075752] 
44. Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, et al. Recommendations for 
evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60(8):1242–51. 
[PubMed: 25609682] 
Kalayjian et al. Page 11
AIDS. Author manuscript; available in PMC 2019 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1: 
Scatter plots of baseline BMD and 48-week changes from baseline BMD with serum 
phosphate (1A), 48-week AUC-fractional excretion of phosphate (1B) and 48-week changes 
from baseline in GFR.
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Figure 2: 
Scatter plots of 48-week changes from baseline of BMD of spine (2A) and hip (2B) with 48-
week changes from baseline of CD4 cell counts.
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